Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSPI targets juice capsules

This article was originally published in The Tan Sheet

Executive Summary

FDA should halt the marketing of NSA's Juice Plus+ Orchard Blend and Juice Plus+ Garden Blend capsules because the products appear to be adulterated and misbranded, the Center for Science in the Public Interest says in a letter to the agency Dec. 12. CSPI says it is concerned the products' claim, "the next best thing to fruits and vegetables," may lead consumers to believe the pills are "closer to real fruits and vegetables than is likely to be the case." The labels say the capsules contain high levels of vitamins A and C and folate naturally, and do not disclose that these vitamins and minerals are added to the capsules during processing and are nutrients only characteristic of the original fruit and vegetable sources...

You may also be interested in...



Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS101198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel